🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Global Health Concern

Gonorrhoea infections are escalating worldwide, with data suggesting over 82 million new cases annually. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices currently available.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The global health body has listed it as a "priority pathogen". A tracking program showed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a major breakthrough in the management of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to findings published in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses two antibiotics. The research included over 900 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Doctors treating patients have voiced positive views. Having a one-pill regimen of this kind is described as a "game-changer" for public health efforts. This is considered crucial to reduce the burden of the disease for individuals and to stop the proliferation of untreatable gonorrhoea globally.